< Back to previous page
Publication
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial
Journal Contribution - Journal Article
Journal: BMC CANCER
ISSN: 1471-2407
Issue: 1
Volume: 20
Publication year:2020
Accessibility:Open
- See also: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
- See also: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial